Lantheus Holdings, Inc. (LNTH)
Nasdaq: LNTH · In Vitro & In Vivo Diagnostic Substances · North Billerica, MA · filing with the SEC since 2014
Grade6.8
◀ Past 8.7● Present 7.1▶ Future 4.5
Who owns Lantheus Holdings, Inc.
As filed with the SECHolders of 5% or more
6
Farallon Capital Management, L.L.C. holds 8.6% of Common Stock, par value $0.01 per share (the "Shares"), as its SCHEDULE 13G/A filed Aug 13, 2026 says.
Directors and officers
16
report now, of 37 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.01 per share (the "Shares")
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 5, 2026 · Common Stock, par value $0.01 per share (the "Shares") · 5.1% in Nov 12, 2025
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 8.6% in Feb 17, 2026
Fmr LLC
SCHEDULE 13G/A · filed Nov 5, 2025 · COMMON STOCK · 7.5% in Aug 6, 2025
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Vanguard Portfolio Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Morgan Stanley
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock · reported falling below 5%, from 5.6% in Nov 7, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What LNTH reports owning in othersstakes of 5% or more, and other ties
Radiopharm Theranostics Limited RADX
SCHEDULE 13G · filed Sep 4, 2026 · Ordinary Shares, no par value per share
Perspective Therapeutics, Inc. CATX
SCHEDULE 13D/A · filed Sep 23, 2026 · Common Stock, $0.001 par value
Other ties the annual report names
Radiopharm Theranostics Limited
An investee · investee · invested in, named in the 10-K filed Feb 26, 2026
Life Molecular Imaging Ltd
A company bought · acquisition · Jul 2025 · owns, named in the 10-K filed Feb 26, 2026
Evergreen Theragnostics
A company bought · acquisition · Mar 2025 · owns, named in the 10-K filed Feb 26, 2026
Life Molecular Imaging, RM2 Technology
A company bought · asset acquisition · owns, named in the 10-K filed Feb 26, 2026
POINT Biopharma
A company bought · asset acquisition · owns, named in the 10-K filed Feb 26, 2026
32 subsidiaries in 7 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.